The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?

摘要: The risk of stroke in patients with non-valvular atrial fibrillation (NVAF) varies widely depending on patient age and the presence other factors such as hypertension, diabetes mellitus, congestive heart failure or prior transient ischaemic attack (TIA) (1, 2). Warfarin reduces by about twothirds when compared to placebo no treatment, two-fifths aspirin, but substantially increases major bleeding (2, 3). most feared complication warfarin is intracranial which occurs at rate 2–5 per 1,000 year often results disability death (3). Consequently, decision use must balance benefits for prevention against bleeding. goal prediction models help clinicians select appropriate antithrombotic therapy prevention. Because absolute benefit increasing baseline whereas more constant (3, 4), between risks individual determined primarily their untreated risk. In this paper we critically examine value CHADS2 (acronym recent Congestive failure, history Hypertension, Age≥75 years, Diabetes past Stroke TIA) index estimate NVAF.